

FDA Status

FDA has approved the use of verteporfin for predominantly classic subfoveal choroidal neovascularization (CNV), as determined by fluorescein angiography, due to age-related macular degeneration (AMD), presumed ocular histoplasmosis, or pathologic myopia.